Bio4t2

What Bio4t2 does

Bio4t2 is a private, early-stage biotechnology company headquartered in San Diego, California, founded in 2019. The firm focuses on the development of CAR-T (chimeric antigen receptor T-cell) cell therapies specifically directed at solid tumors — a therapeutic class in which efficacy has been historically harder to achieve than in the more established hematological cancer indications. According to the firmographic input, Bio4t2 employs between 11 and 50 people and operates as a for-profit private company with no public ticker.

The company's technology position is articulated through a multi-platform architecture comprising four named constructs: PrismCore, Bio-Engine, Bi-CAR-T, and Bio-Strike. This naming pattern indicates a modular approach in which each platform likely addresses a different aspect of the CAR-T challenge for solid tumors — for example, antigen targeting, cell engineering, dual-antigen receptor design, and effector function — though the inputs do not specify the molecular or functional differentiation between these platforms. No patents, publications, or third-party validation were disclosed in the data provided.

As a preclinical-stage biotech, Bio4t2's business model is consistent with the standard sector pattern: R&D activity is funded by equity capital (amounts undisclosed), with future monetization contingent on either out-licensing of platform technology, development partnerships with larger pharma, co-development deals, or eventual commercialization of an approved therapy. No pricing model, customer list, GTM motion, distribution channel, partnership, or revenue figure was available from the firm's web properties — the company website only returned a verification splash page — so commercial mechanics beyond company formation cannot be characterized.

Name

Bio4t2

Website

https://bio4t2.com

Company type

Private

Founded year

2019

Headcount range

1–10 employees

Short description

Bio4t2 is a San Diego-based private biotechnology company founded in 2019 that develops CAR-T cell therapies for solid tumors using proprietary platforms including PrismCore, Bio-Engine, Bi-CAR-T, and Bio-Strike.

Ownership category

akta.pro rank

Product category

Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• CAR-T cell therapy
• Solid tumor therapy
• Cell therapy platforms
• Cancer immunotherapy
• Oncology biotechnology

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Bio4t2 develops CAR-T cell therapies targeting solid tumors. The company leverages a set of proprietary technology platforms — PrismCore, Bio-Engine, Bi-CAR-T, and Bio-Strike — to engineer and advance its cell therapy candidates for oncology applications.

Differentiator

Problem solved

Functional benefit

Products and services

• CAR-T cell therapies for solid tumors

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Direct peers

• Adaptimmune: Develops engineered T-cell therapies (SPEAR T-cells) for solid tumors — closely comparable in therapeutic area (solid tumor cell therapy) and engineered-T-cell modality.
• Cellectis: Pioneer in gene-edited allogeneic CAR-T using TALEN-based cell engineering — directly comparable technology category to Bio4t2's Bio-Engine and Bi-CAR-T platforms.
• Fate Therapeutics: Develops iPSC-derived NK and T-cell therapies, including off-the-shelf CAR-T candidates. Closely comparable cell therapy platform model with similar engineering-first philosophy.
• Caribou Biosciences: Clinical-stage allogeneic CAR-T developer using CRISPR-based cell engineering — directly comparable to Bio4t2's engineering-platform approach (Bio-Engine) for next-generation cell therapies.
• Nkarta: Develops CAR-NK and CAR-T cell therapies with an engineering-platform orientation, broadly comparable in cell therapy modality and preclinical-to-clinical stage.
• Eureka Therapeutics: Clinical-stage biotech developing CAR-T and TCR-mimic therapies specifically for solid tumors, the same core indication Bio4t2 pursues. Comparable in mission and modality focus.
• Allogene Therapeutics: Leading allogeneic CAR-T company targeting both hematologic and solid tumors. Comparable as a CAR-T-focused peer with multi-program pipeline ambitions.

Emerging players

• Adicet Bio: Develops gamma delta CAR-T cell therapies for hematologic and solid tumors, a partially overlapping modality and indication footprint with Bio4t2.
• Precision Biosciences: Uses ARCUS genome editing to engineer allogeneic CAR-T cells — comparable as an engineering-platform-driven cell therapy developer with overlapping modality.

Broad incumbents

• CRISPR Therapeutics: Established gene-editing biotech with commercial-stage Casgevy and a pipeline of CAR-T candidates. Comparable modality (engineered cell therapies) but at materially larger scale and broader portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bio4t2